Literature DB >> 28873996

Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.

Wi Jin Kim1, W Christopher Newman1, Nduka M Amankulor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28873996     DOI： 10.1093/neuros/nyx263

Source DB:  PubMed          Journal:  Neurosurgery        ISSN： 0148-396X            Impact factor:   4.654


× No keyword cloud information.
  4 in total

1.  A Nanobody Against Cytotoxic T-Lymphocyte Associated Antigen-4 Increases the Anti-Tumor Effects of Specific CD8+ T Cells.

Authors:  Zhuoran Tang; Fengzhen Mo; Aiqun Liu; Siliang Duan; Xiaomei Yang; Liu Liang; Xiaoqiong Hou; Shihua Yin; Xiaobing Jiang; Natalia Vasylieva; Jiexian Dong; Bogdan Barnych; Bruce D Hammock; Xiaoling Lu
Journal:  J Biomed Nanotechnol       Date:  2019-11-01       Impact factor: 3.641

Review 2.  Potential Epigenetic-Based Therapeutic Targets for Glioma.

Authors:  Lanlan Zang; Shukkoor Muhammed Kondengaden; Fengyuan Che; Lijuan Wang; Xueyuan Heng
Journal:  Front Mol Neurosci       Date:  2018-11-15       Impact factor: 5.639

3.  PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models.

Authors:  Shanyue Sun; Guangying Du; Jiang Xue; Jinbo Ma; Minmin Ge; Hongbo Wang; Jingwei Tian
Journal:  Int J Immunopathol Pharmacol       Date:  2018 Jan-Dec       Impact factor: 3.219

Review 4.  Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.

Authors:  Shabierjiang Jiapaer; Takuya Furuta; Shingo Tanaka; Tomohiro Kitabayashi; Mitsutoshi Nakada
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-09-21       Impact factor: 1.742
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.